Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Lille
About this trial
This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (≥ 18 years)
Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist
Disqualifiers
Patients under legal protection
Patients refusing the reuse of their data after individual information
Trial population
Patients who underwent scintigraphy for reasons other than suspected amyloidosis
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Cardiac amyloidosis diagnosis
Time frame
After the reassessment evaluation (one-day evaluation)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Lille
Lead sponsor
Pfizer
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: